Affiliation:
1. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology; Pavlov First St. Petersburg State Medical University
2. St. Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko; I.I. Mechnikov North-western Medical State University
3. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
4. St. Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko
5. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology; King's College London
Abstract
The aim of this study is to examine the relationship between the severity and duration criteria of COVID-19 and the psychopharmacotherapy administered to patients in within a psychiatric hospital.Materials and Methods. We analyzed 169 case histories involving completed clinical cases of COVID-19 treatment in a specialized infectious psychiatric department in St. Petersburg, covering the period from May 2020 to January 2021. Correlation, dispersion, and regression analyses were employed to evaluate severe and mild COVID-19 progression indicators, as well as the duration of persistent SARS-CoV-2 viral shedding. We assessed the clinical and laboratory parameters in patients, along with the psychopharmacotherapy administered, including antidepressants, antipsychotics, and acid sphingomyelinase inhibitors (FIASMA-active drugs).Results. Cardiovascular diseases emerged as a predictor of severe COVID-19 when combined with an increasing platelet-to-lymphocyte ratio (PLR), increasing the risk of severe course by over two-fold. The use of any psychotropic agents was associated with a 0.9% increase in the risk of severe course of COVID-19 for each unit increase in the systemic inflammation index PLR, specifically in patients with intellectual disability (ICD-10 codes F70-79), when compared to patients with schizophrenia (ICD-10 codes F20-29). High PLR values and the use of FIASMA-active drugs were associated with prolonged COVID-19 duration, while antidepressant therapy and elevated C-reactive protein levels were associated with a reduced predicted duration of viral shedding in 13.8% of variance. Additional consideration of the nosology of psychiatric disorders in the regression model increased the proportion of explained variance to 22.8%.Conclusion. Consideration should be given to thymoanaleptic therapy for individuals with psychiatric disorders during periods of increased disease incidence leading up to potential SARS-CoV-2 infection, as it may serve as a protective factor against COVID-19. Furthermore, there is no evidence to suggest adverse effects of antipsychotics on the severity and duration of COVID-19. Further research is required to investigate the effects of FIASMA-active psychopharmacological agents within nosologically homogeneous groups.
Publisher
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology
Reference21 articles.
1. Mosolov SN, Malin DI, Tsukarzi EE, Kostyukova EG. Drug Therapy for Patients with Mental Disorders Who Have a Coronavirus Infection (COVID-19). Sovremennaya terapiya psihicheskih rasstrojstv. 2020;(2):34-39. (InRuss.). https://doi.org/10.21265/PSYPH.2020.18.69.0015.
2. Mosolov SN, Fedorova EYu. The risk of developing cardiovascular disease in bipolar disorder. biological factors and therapy. Terapevticheskii arkhiv. 2022;94(4):579–583. (InRuss.). https://doi.org/10.26442/00403660.2022.04.201455.
3. Neznanov NG, Sorokin MY, Skripov VS, Esina KM. Epidemiology of mental disorders as a marker of psychiatric factors of the COVID-19 pandemic. Rossiiskii psikhiatricheskii zhurnal. 2023;(1):4-13. (InRuss.).
4. Sorokin MYu. Affective and cognitive symptoms in COVID-19 survivors: Implications for organization of Psychiatric Services in the post pandemic and within pandemic period. Byulleten’ medicinskoj nauki. 2022;(3):117–127. (InRuss.). https://doi.org/10.31684/25418475_2022_3_117.
5. Sorokin MYu, Lutova NB, Mazo GE, Neznanov NG, Kasyanov ED, Rukavishnikov GV et al. Structure of anxiety and stress as factors of COVID-19 vaccine acceptance. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2021;55(2):52–61. (InRuss.). https://doi.org/10.31363/2313-7053-2021-55-2-52-61. (In Russ.)